Search Results 571-580 of 17394 for alopecia

  1. Mayo Clinic

    Many people's idea of a traditional breakfast is eggs, sausage and white toast, which leaves little room for fruits, vegetables or whole grains.

  2. A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

    Ongoing toxic manifestations of previous treatments > Grade 2 with the exception of alopecia and neuropathy. Subjects with treated brain metastases with ...

  3. Mayo Clinic

    ... . IMG-20451390. Home; cc-confident-woman-business_tablet. 5X Challenge is here! 5X My Gift! Your gift today can have 5X the impact on AI research and ...

  4. Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma - Mayo Clinic

    Toxicities due to prior therapy must be stable and recovered to Grade ≤ 1 (except for clinically nonsignificant toxicities such as alopecia). Age 18 or ...

  5. A Study to Evaluate the Safety and Effectiveness of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer - Mayo Clinic

    With the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment;; Spinal cord ...

  6. Retinal diseases - Symptoms and causes - Mayo Clinic

    Types · Retinal tear. · Retinal detachment. · Diabetic retinopathy. · Epiretinal membrane. · Macular hole. · Macular degeneration. · Retinitis pigmentosa.

  7. A Study to Test Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases - Mayo Clinic

    ... alopecia and =< grade 2 neuropathy, which are allowed; Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion ...

  8. Brightcove-Orthopedic surgery home

    Cedric Ortiguera, M.D., Orthopedic Surgery, Mayo Clinic: So when patients come here to Mayo, I think they know that they're going to get the right treatment ...

  9. A Study of ASTX660 Alone or Combined with ASTX727 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) - Mayo Clinic

    ... alopecia). Hypersensitivity to decitabine, ASTX727, ASTX660, or any of their excipients. Liver cirrhosis, or chronic liver disease Child-Pugh Class B or C ...

  10. A Study to Assess the Effectiveness, Safety, and Drug/Body Interactions of Rovalpituzumab for Third-Line and Later Treatment of Patients with Small Cell Lung Cancer that has Returned or is Resistant to Treatment - Mayo Clinic

    ... alopecia) prior to initiation of study drug administration; Adequate hematologic and organ function as confirmed by laboratory values; Last dose of any prior ...